Intent to Sole Source - BD Bioscience Reagents
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), Office of Logistics and Acquisitions, has issued a Notice of Intent to Sole Source for the procurement of BD Bioscience reagents and consumables. This acquisition is for clinical patient-care quality control flow cytometry assays at the NIH Clinical Center in Bethesda, MD. The NIH intends to negotiate with BD Biosciences due to proprietary, FDA-validated reagents essential for existing protocols. Capability statements from other responsible sources are due by March 7, 2026, 11:00 AM EST.
Purpose & Justification
The NIH's Center of Cellular Engineering (CCE), Department of Transfusion Medicine, requires these reagents for its AABB-accredited cellular therapy laboratory. The lab supports NIH's intramural clinical trials by manufacturing cellular therapies for patients with various diseases, adhering to FDA guidelines. The sole-source justification is based on 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1, citing BD Biosciences as the only responsible source. Substituting these specific reagents would necessitate extensive re-validation, posing significant risks to patient care, clinical trials, and incurring substantial delays and costs.
Scope of Work
The requirement is for the purchase of monoclonal antibodies, assay quality controls, buffers, sheath fluids, and disposable components on an as-needed basis. These supplies will support approximately 100 flow cytometry assays per year using the FACSLyris flow cytometer instrument. The scope includes a comprehensive list of specific BD™ antibodies, buffers, control beads, and consumables, along with technical support at no additional cost. Special requirements include minimum shelf life for reagents (90 days) and disposables (6 months), and overnight shipping.
Contract Details & Timeline
- Opportunity Type: Special Notice (Notice of Intent to Sole Source)
- Sole Source Vendor: BD Biosciences
- Estimated Value: $1,776,695.83 for a 5-year contract
- Contract Type: Firm-fixed-price
- Period of Performance: Anticipated February 1, 2026, to September 30, 2030 (12-month base + three 12-month option periods)
- Set-Aside: None (Sole Source)
- Capability Statement Due: March 7, 2026, by 11:00 AM EST
- Published Date: February 25, 2026
Response Information
This is not a Request for Proposal. All responsible sources that believe they can provide the required items may submit a capability statement. Statements should be emailed to valerie.gregorio@nih.gov with the subject line NOI-CC-26-002633. The government will consider all responses received by the closing date, but a determination not to compete this requirement remains at the government's discretion.